Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 146

1.

Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia.

Raspadori D, Pacelli P, Sicuranza A, Abruzzese E, Iurlo A, Cattaneo D, Gozzini A, Galimberti S, Baratè C, Pregno P, Nicolosi M, Sorà F, Annunziata M, Luciano L, Caocci G, Moretti S, Sgherza N, Fozza C, Russo S, Usala E, Liberati MA, Ciofini S, Trawinska MM, Gozzetti A, Bocchia M.

Cytometry B Clin Cytom. 2019 Jul;96(4):294-299. doi: 10.1002/cyto.b.21764. Epub 2019 Feb 3.

2.

Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.

Cencini E, Sicuranza A, Fabbri A, Ferrigno I, Rigacci L, Cox MC, Raspadori D, Bocchia M.

Br J Haematol. 2019 Jan;184(2):223-231. doi: 10.1111/bjh.15582. Epub 2018 Sep 11.

PMID:
30203425
3.

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.

Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, Fava C, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baratè C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D.

Front Oncol. 2018 May 30;8:194. doi: 10.3389/fonc.2018.00194. eCollection 2018.

4.

Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.

Zurli V, Wimmer G, Cattaneo F, Candi V, Cencini E, Gozzetti A, Raspadori D, Campoccia G, Sanseviero F, Bocchia M, Baldari CT, Kabanova A.

Blood. 2017 Nov 2;130(18):2006-2017. doi: 10.1182/blood-2017-03-775858. Epub 2017 Sep 20.

PMID:
28931525
5.

High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.

Tiribelli M, Raspadori D, Geromin A, Cavallin M, Sirianni S, Simeone E, Bocchia M, Fanin R, Damiani D.

Leuk Res. 2017 Jul;58:31-38. doi: 10.1016/j.leukres.2017.04.001. Epub 2017 Apr 4.

PMID:
28407515
6.

Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.

Damiani D, Tiribelli M, Raspadori D, Sirianni S, Meneghel A, Cavalllin M, Michelutti A, Toffoletti E, Geromin A, Simeone E, Bocchia M, Fanin R.

Oncotarget. 2015 Oct 6;6(30):30212-21. doi: 10.18632/oncotarget.4901.

7.

Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.

Gozzetti A, Candi V, Fabbri A, Schiattone L, Cencini E, Lauria F, Frasconi A, Crupi R, Raspadori D, Papini G, Defina M, Bartalucci G, Bocchia M.

Leuk Res. 2014 Aug;38(8):891-5. doi: 10.1016/j.leukres.2014.05.016. Epub 2014 Jun 2.

PMID:
24934847
8.

Identification of a novel p190-derived breakpoint Peptide suitable for Peptide vaccine therapeutic approach in ph+ acute lymphoblastic leukemia patients.

Ippoliti M, Defina M, Gozzini A, Baratè C, Aprile L, Pietrini A, Gozzetti A, Raspadori D, Lauria F, Bocchia M.

Leuk Res Treatment. 2012;2012:150651. doi: 10.1155/2012/150651. Epub 2012 Feb 15.

9.

A central nervous system CD56 positive multiple myeloma patient with a t(11;14) (q11;q32): a case report.

Gozzetti A, Cerase A, Crupi R, Raspadori D, Defina M, Bocchia M, Lauria F.

Leuk Res. 2011 Nov;35(11):e206-8. doi: 10.1016/j.leukres.2011.06.034. Epub 2011 Jul 20. No abstract available.

PMID:
21767877
10.

A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction.

Cencini E, Sozzi E, Sicuranza A, Fabbri A, Raspadori D, Lauria F, Forconi F.

Br J Haematol. 2011 Jul;154(2):271-4. doi: 10.1111/j.1365-2141.2011.08602.x. Epub 2011 Apr 26. No abstract available.

PMID:
21521181
11.

Insight into the behavior of hairy cell leukemia by immunogenetic analysis.

Forconi F, Cencini E, Sozzi E, Sicuranza A, Raspadori D, Lauria F.

Leuk Lymphoma. 2011 Jun;52 Suppl 2:103-7. doi: 10.3109/10428194.2011.569620. Epub 2011 Apr 19. Review.

PMID:
21504291
12.

Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia.

Sozzi E, Amato T, Sahota SS, Nuti S, Raspadori D, Sicuranza A, Cencini E, Tosi P, Lauria F, Forconi F.

Hematol Oncol. 2011 Mar;29(1):31-7. doi: 10.1002/hon.952.

PMID:
20658474
13.

A der(1)t(1;21)(p36.3;q22) in a patient with acute myelogenous leukemia M2.

Gozzetti A, Crupi R, Rondoni M, Defina M, Bocchia M, Pietrini A, Raspadori D, Lauria F.

Acta Haematol. 2010;124(1):44-5. doi: 10.1159/000314075. Epub 2010 Jul 3. No abstract available.

PMID:
20606416
14.

Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia.

Gozzetti A, Crupi R, Rondoni M, Daviddi B, Defina M, Bocchia M, Pietrini A, Raspadori D, Lauria F.

Cancer Genet Cytogenet. 2010 Feb;197(1):84-5. doi: 10.1016/j.cancergencyto.2009.05.006. No abstract available.

PMID:
20113843
15.

Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia.

Capitani N, Lucherini OM, Sozzi E, Ferro M, Giommoni N, Finetti F, De Falco G, Cencini E, Raspadori D, Pelicci PG, Lauria F, Forconi F, Baldari CT.

Blood. 2010 May 6;115(18):3726-36. doi: 10.1182/blood-2009-08-239244. Epub 2010 Jan 8.

PMID:
20061561
16.

Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior.

Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, Rigacci L, Gherlinzoni F, Cantaffa R, Baraldi A, Gallamini A, Zaccaria A, Pulsoni A, Gobbi M, Tassi M, Raspadori D, Leoncini L, Rinaldi A, Sabattini E, Bertoni F, Pileri SA, Lauria F.

Blood. 2009 Nov 19;114(21):4696-702. doi: 10.1182/blood-2009-03-212449. Epub 2009 Aug 10.

PMID:
19667403
17.

Isolated deletion of 6q in a patient with myelodysplastic syndrome.

Gozzetti A, Crupi R, Defina M, Bocchia M, Raspadori D, Lauria F.

Cancer Genet Cytogenet. 2009 Jul;192(1):51. doi: 10.1016/j.cancergencyto.2009.02.014. No abstract available.

PMID:
19480939
18.

The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors.

Rossi D, Sozzi E, Puma A, De Paoli L, Rasi S, Spina V, Gozzetti A, Tassi M, Cencini E, Raspadori D, Pinto V, Bertoni F, Gattei V, Lauria F, Gaidano G, Forconi F.

Br J Haematol. 2009 Jun;146(1):64-75. doi: 10.1111/j.1365-2141.2009.07711.x. Epub 2009 May 5.

PMID:
19438485
19.

Higher expression of BDNF receptor gp145trkB is associated with lower apoptosis intensity in T cell lines in multiple sclerosis.

De Santi L, Cantalupo L, Tassi M, Raspadori D, Cioni C, Annunziata P.

J Neurol Sci. 2009 Feb 15;277(1-2):65-70. doi: 10.1016/j.jns.2008.10.006. Epub 2008 Nov 6.

PMID:
18992902
20.

Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion.

Forconi F, Rinaldi A, Kwee I, Sozzi E, Raspadori D, Rancoita PM, Scandurra M, Rossi D, Deambrogi C, Capello D, Zucca E, Marconi D, Bomben R, Gattei V, Lauria F, Gaidano G, Bertoni F.

Br J Haematol. 2008 Nov;143(4):532-6. doi: 10.1111/j.1365-2141.2008.07373.x. Epub 2008 Aug 24.

PMID:
18752589

Supplemental Content

Loading ...
Support Center